| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.7M | — | -47.2% |
| SG&A Expense | $1.7M | — | +11.3% |
| Operating Income | -$3.4M | — | +28.7% |
| Net Income | -$3.3M | — | +26.6% |
| EPS (Basic) | -$0.30 | — | +28.6% |
| EPS (Diluted) | -$0.30 | — | +28.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.9M | +11.2% | -22.9% |
| Short-term Investments | $1.4M | -75.3% | -89.5% |
| Current Assets | $7.1M | -34.7% | -66.1% |
| Total Assets | $7.2M | -34.5% | -65.8% |
| Current Liabilities | $3.8M | -16.1% | -11.9% |
| Total Liabilities | $3.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.8M | — | +13.8% |
| Capital Expenditures | $1K | — | +0.0% |
| Investing Cash Flow | $4.3M | — | +31.2% |
| Free Cash Flow | -$3.8M | — | +13.8% |
| -12.6% |
| Stockholders' Equity | $3.4M | -47.3% | -79.5% |